Clinical trial
Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
NCT00125346 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00125346 |
|---|---|
| Title | Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects |
| Acronym | EVOLVE |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Tobramycin Inhalation Powder |
| Enrollment | 98 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Aug 1, 2005 |
| Last update posted | Oct 12, 2011 |
| Countries | Argentina, Brazil, Bulgaria, Canada, Chile, Lithuania, Mexico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: